Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bi-Specific Maker Covagen’s Series B To Progress Lead Asset COVA322

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss biotech Covagen’s potential for engineering antibodies with two distinct binding specificities for a wide range of clinical applications as targeted agents has secured it a $47 million tranched Series B financing – which could rise to $63 million – to fund development of its lead asset, a bispecific TNF/IL-17A inhibitor.

You may also be interested in...



Arena Cannabinoid Pain Compound Misses In Phase IIb IBS Trial

Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant

Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel